Enovis Corporation/$ENOV

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Enovis Corporation

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

Ticker

$ENOV

Primary listing

NYSE

Industry

Health Care Equipment and Supplies

Employees

7,367

ENOV Metrics

BasicAdvanced
$1.6B
-
-$14.50
1.81
-

Bulls say / Bears say

Enovis Corporation reported an 8% increase in first-quarter 2025 sales, with Reconstructive sales growing by 11% year-over-year, indicating strong demand for their orthopedic products. (globenewswire.com)
The company raised its full-year 2025 revenue guidance to approximately $2.22-2.25 billion, reflecting confidence in sustained growth and market expansion. (stocktitan.net)
Analysts have set an average target price of $56.50 for Enovis stock, suggesting a potential upside of 71.78% from its current price, indicating strong market confidence. (directorstalkinterviews.com)
Enovis reported a net loss from continuing operations of $56 million in the first quarter of 2025, highlighting ongoing profitability challenges. (stocktitan.net)
The company's operating margin declined to -8.4% in Q1 2025, down from -6.8% in the same quarter last year, indicating worsening operational efficiency. (stockstory.org)
D. E. Shaw & Co. Inc. reduced its stake in Enovis by 89.9% during the fourth quarter, potentially signaling decreased confidence from institutional investors. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ENOV

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs